Coldstream Capital Management Inc. Acquires 370 Shares of Pfizer Inc. (NYSE:PFE)

Share on StockTwits

Coldstream Capital Management Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 93,715 shares of the biopharmaceutical company’s stock after acquiring an additional 370 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Pfizer were worth $4,059,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Veritas Investment Management LLP bought a new position in Pfizer during the 4th quarter valued at about $247,000. Torch Wealth Management LLC increased its position in shares of Pfizer by 2.2% during the 4th quarter. Torch Wealth Management LLC now owns 45,716 shares of the biopharmaceutical company’s stock valued at $1,996,000 after purchasing an additional 1,000 shares during the last quarter. Beacon Pointe Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $2,550,000. Atwood & Palmer Inc. increased its position in shares of Pfizer by 20.6% during the 4th quarter. Atwood & Palmer Inc. now owns 22,246 shares of the biopharmaceutical company’s stock valued at $971,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Beacon Pointe Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $1,118,000. 71.68% of the stock is currently owned by hedge funds and other institutional investors.

PFE traded up $0.18 during trading on Friday, reaching $36.69. 40,533,788 shares of the company traded hands, compared to its average volume of 19,846,088. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The firm has a fifty day simple moving average of $36.00 and a 200 day simple moving average of $40.56. The company has a market cap of $201.22 billion, a P/E ratio of 12.23, a PEG ratio of 2.89 and a beta of 0.65.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business had revenue of $13.26 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the firm posted $0.77 EPS. The company’s revenue was down 1.5% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.81 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, August 2nd were issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.92%. The ex-dividend date was Thursday, August 1st. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

PFE has been the subject of several research reports. Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Goldman Sachs Group reissued a “buy” rating and issued a $49.00 target price on shares of Pfizer in a report on Monday, June 17th. Morgan Stanley reduced their target price on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Bank of America lowered shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Finally, ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a report on Saturday, September 14th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $45.88.

In other news, major shareholder Pfizer Inc bought 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Scott Gottlieb bought 3,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Stocks Increasing Dividends

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Investment Analysts’ Price Target Changes for October, 14th
Investment Analysts’ Price Target Changes for October, 14th
Civic  Market Cap Achieves $26.92 Million
Civic Market Cap Achieves $26.92 Million
TRAXIA Tops 24-Hour Trading Volume of $207.00
TRAXIA Tops 24-Hour Trading Volume of $207.00
TOP  Price Hits $0.0022
TOP Price Hits $0.0022
Syndax Pharmaceuticals  Stock Rating Upgraded by Zacks Investment Research
Syndax Pharmaceuticals Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America  Stock Rating Upgraded by Zacks Investment Research
Laboratory Corp. of America Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.